What is Amgen's TEPEZZA — total revenues?

Amgen (AMGN) reported TEPEZZA — total revenues of $490M in Q1 2026.

How has Amgen's TEPEZZA — total revenues changed year-over-year?

Amgen's TEPEZZA — total revenues increased by 28.6% year-over-year, from $381M to $490M.

What does TEPEZZA — total revenues mean?

This metric represents the total gross revenue generated from the sales of a specific therapeutic product line within the company's portfolio. It reflects the market adoption, pricing power, and clinical demand for this particular drug treatment. Monitoring this revenue stream helps investors assess the product's lifecycle stage and its contribution to the overall biopharmaceutical segment performance.

Amgen AMGN TEPEZZA — Total revenues

Other product segments

Repatha

$3.02B—

Other products

$1.53B+3.6%

Prolia

$727M-33.8%

EVENITY

$562M+27.1%

Otezla

$431M-1.4%

BLINCYTO

$415M+12.2%

Nplate

$412M+31.6%

XGEVA

$411M-27.4%

TEZSPIRE

$343M+20.4%

KYPROLIS

$330M+1.9%

ENBREL

$320M-37.3%

Aranesp

$311M-8.5%

Vectibix

$287M+7.5%

UPLIZNA

$262M+188%

IMDELLTRA/IMDYLLTRA

$258M+219%

KRYSTEXXA

$255M+8.1%

Similar metrics at other companies

INCYPEMAZYRE — Total revenues

$23.42M+5.5%

GILDTecartus — Total revenues

$75M-3.8%

BMYZeposia — Total Revenues

$169M+12.7%

GILDYeztugo — Total revenues

$166M—

ARDXXPHOZAH — Total revenues

$23.3M-0.5%

GEHCProduct — Total revenues

$3.42B+4.7%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$212.16B+30.0%

Enterprise value$268.92B+22.9%

P/E27.2×+2.5×

P/S5.7×+1.0×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's tepezza — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's TEPEZZA — total revenues?: Amgen (AMGN) reported TEPEZZA — total revenues of $490M in Q1 2026.
How has Amgen's TEPEZZA — total revenues changed year-over-year?: Amgen's TEPEZZA — total revenues increased by 28.6% year-over-year, from $381M to $490M.
What does TEPEZZA — total revenues mean?: This metric represents the total gross revenue generated from the sales of a specific therapeutic product line within the company's portfolio. It reflects the market adoption, pricing power, and clinical demand for this particular drug treatment. Monitoring this revenue stream helps investors assess the product's lifecycle stage and its contribution to the overall biopharmaceutical segment performance.